Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) and IBM announced a new partnership on Thursday. The Israeli pharmaceutical giant was selected as the first Foundational Life Sciences Partner for the Watson Health Cloud program, gaining access to its big data capabilities.
IBM’s Watson is the first commercially available cognitive computing platform that can process natural language queries and crunch vast amounts of data. Teva plans to use the global technology platform to design treatments for “unmet and emerging patients” including millions of people who suffer from chronic conditions like asthma, migraine, and pain.
“By building on the Watson Health Cloud, we believe Teva will be in a unique position to put the best information and insights in the hands of physicians, care teams and patients, to empower treatment optimization for individuals and populations across the spectrum of acute and chronic conditions,” said Teva SVP Guy Hadari.
The two firms will also create a joint Teva-IBM Research team that will use big data to model diseases and potential therapeutic treatments.
“Teva’s pioneering digital health vision, reach across global markets, extensive portfolio of medicines and significant industry experience make them a preferred life science ecosystem partner for the Watson Health Cloud,” said IBM Watson SVP Mike Rhodin.
Teva, as one of the largest pharmaceutical companies in the world, will help IBM to improve the Watson Health Cloud’s capabilities and its integration with existing Watson Health ecosystem partners. The Israeli firm expects its work with IBM on the long-range platform to lead to the development of solutions designed by the analysis of real world evidence.
“Watson holds promise to provide Teva with better insights, real-time feedback and options for clinicians to consider to improve patient care,” added Teva’s Hadari.
Published by Globes [online], Israel business news - www.globes-online.com - on September 9, 2015
© Copyright of Globes Publisher Itonut (1983) Ltd. 2015